| abstract |
The present disclosure provides compounds having Bcl inhibitory activity. Phosphoridine compounds may include P-phenylphosphoridine moieties substituted with N-aryl or N-heteroaryl groups. The P-phenylphosphoridine moiety may be substituted with thio (= S) in phosphorus instead of oxo (= O). The second heteroatom attached to phosphorus may be cyclically attached to the N-substituted nitrogen atom of the phosphorus attached to phosphorus and combined through the phosphorus atom to which they are attached to provide a heterocycle. By incorporating such a cyclic constraint between the two phosphorus substituents at the core binding moiety, favorable binding conformations can be promoted in the compound. Since the selected compounds promote apoptosis in senescent cells, they can be developed to treat aging-related conditions such as osteoarthritis, eye disease, lung disease, and atherosclerosis. The selected compound promotes apoptosis in cancer cells and can be developed as a chemotherapeutic agent. |